Jasper Therapeutics has secured a financial lifeline by merging with Kira Pharmaceuticals, a private immune drug developer, in an all-stock deal that includes raising $132 million in a private stock offering. This merger revitalizes Jasper, which was struggling with just $14 million in cash, allowing it to operate until late 2028. The combined company retains the Jasper name and adds Kira’s two immune disease drugs to its pipeline, enhancing its prospects following past setbacks, including a product issue that led to significant layoffs. Kira’s drugs are focused on immune-related conditions, with promising early data indicating strong potential in treating various diseases.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biopharmadive.com/news/jasper-kira-merger-mirador-immune-drugs/825533/
